Background: Young patients (aged < 40 years) with type 2 diabetes (T2D) have a high lifetime risk of developing cardiovascular disease (CVD). However, little is known about the CVD risk profile of this cohort in the UK primary care setting. Aim: To determine CVD risk profile of young patients with T2D without CVD compared to older (aged >40 years) subjects. Design: A cross-sectional study using The Health Improvement Network (THIN) database, which contains anonymized patient information from more than 300 general practices throughout England and Wales. Methods: T2D subjects above the age of 18 years without previous CVD and not on lipid or blood pressure lowering therapy were randomly selected. Data on glycaemic control and CVD risk factors [weight, body mass index (BMI), lipid profile] were collected. Results: A total of 49 919 patients with T2D were identified, of whom 2756 (0.5%) and
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Background: Young patients (aged < 40 years) with type 2 diabetes (T2D) have a high lifetime risk of developing cardiovascular disease (CVD). However, little is known about the CVD risk profile of this cohort in the UK primary care setting. Aim: To determine CVD risk profile of young patients with T2D without CVD compared to older (aged >40 years) subjects. Design: A cross-sectional study using The Health Improvement Network (THIN) database, which contains anonymized patient information from more than 300 general practices throughout England and Wales. Methods: T2D subjects above the age of 18 years without previous CVD and not on lipid or blood pressure lowering therapy were randomly selected. Data on glycaemic control and CVD risk factors [weight, body mass index (BMI), lipid profile] were collected. Results: A total of 49 919 patients with T2D were identified, of whom 2756 (0.5%) and 47 163 (99.5%) were aged below and above 40 years, respectively. Despite being at least 30 years younger (mean age: early vs. later onset; 33.8 vs. 66.9 years, P < 0.001), the proportions of adverse CVD risk profiles for young patients were similar to the older cohort with T2D. For young vs. old patients: the prevalence of BMI >25: 84.4% vs. 85.3%, P = 0.77; total cholesterol >4 mmol/l: 53.4% vs. 53.8%, P = 0.76; systolic hypertension: 58.2 vs. 58.4%, P = 0.36 and diastolic hypertension: 28.1 vs. 28.5%, P = 0.73). Glycaemic controls were similarly suboptimal between the two groups (mean HbA1c: young vs. old; 7.6% vs. 7.5%, P = 0.49). The prevalence of risk factor clustering were also similar between young vs. old patients with T2D. Discussion: Young T2D subjects possess risk factors that confer high lifetime risk for macrovascular complications, and therefore merits aggressive cardioprotective treatment.
Introduction
Historically, the diagnosis of type 2 diabetes (T2D) is made in middle-and older aged men or women and is associated with the presence of insulin resistance, metabolic syndrome and/or obesity. More recently, however, the incidence of T2D diagnosed in younger patients has increased. 1 This parallels with the 70% rise in the prevalence of obesity among individuals aged between 18 and 29 years. 2 The life expectancy of an individual diagnosed with T2D at the age of 40 years is reduced by 8 years when compared with non-diabetes equivalence CVD constitute their major cause of mortality and the relative risk of death is greater in the younger age compared with older age group. 4 Despite this, little is known about the CVD risk profile of younger (<40 years) patients with T2D without previous CVD within the UK primary care setting. Since age is an independent risk factor for developing CVD events, current public health primary CVD prevention strategies have targeted patients with T2D above the age of 40 years old. 5 This is compounded by the fact that cardiovascular prevention trials have largely excluded younger patients with T2D. 5 In view of the rising prevalence of young patients with T2D and their potentially higher life-time burden of atherosclerosis, increased understanding of their CVD risk profiles may help in the development of future guidelines to prevent CVD among young patients with T2D. We therefore aimed to investigate the CVD and metabolic profile of young and older patients with T2D attending routine care in the primary care setting.
Research design and methods
This was a cross-sectional study using data from The Health Improvement Network (THIN), which contains anonymized patients' information from more than 300 general practices throughout England and Wales and is similar in structure and scope to the General Practice Research database. 6 Sample composed of randomly selected men and women with T2D above the age of 18 years without previous CVD events and not on lipid or blood pressure lowering therapy. T2D was defined as non-insulin requiring for >12 months after diagnosis of diabetes. Each patient data were collected for, body mass index (BMI), systolic and diastolic blood pressure, HbA1c and lipid profile (total cholesterol, LDL cholesterol and triglyceride). All statistics were performed by statistical package social sciences (SPSS) for windows. Significance difference was tested by one-way ANOVA. P-value < 0.05 was considered to be statistically significant. The study received ethics approval from the London NREC.
Results
Patient characteristics are outlined in Table 1 . Overall, 49 919 patients with T2D were identified, of whom 2756 (0.5%) and 47 163 (99.5%) were aged below and above 40 years respectively. Mean age for young vs. old patients with T2D were 33.8 and 66.9 years, respectively. Overall, the cardiovascular risk and metabolic profiles between young and older patients with type 2 diabetes in this large primary care cohort is similar. Both cohorts had similar BMI (mean values for young vs. old T2D were: 31.2 vs. 31.3 kg/m 2 ). The prevalence of patients with BMI >25 were similar between young and older patients with T2D (84.5% vs. 85.3%, P = 0.77).
The prevalence of adverse lipid profiles (cholesterol >4 mmol/l; LDL cholesterol >2 mmol/l) were similar between young and older patients with T2D: 53.4% vs. 53.8%, P = 0.8 and 34.3% vs. 32.6%, P = 0.2; respectively. Mean cholesterol was 4.2 mmol/l and mean LDL cholesterol was 2.2 mmol/l for both young and older patients with T2D. The prevalence of sub-optimal glycaemic control (HbA1c >7%) 5 were similar between the young and older T2D patients (56.1% vs. 55.7%, P = 0.76) with a mean of HbA1c at 7.6 and 7.5%, respectively. Lastly, mean systolic and diastolic blood pressure in the young vs. old patients with T2D were 136 and 76 mmHg, respectively. The prevalence of high systolic blood pressure (>130 mmHg) were 58.2 and 58.4%, respectively, for young vs. old T2D patients (P = 0.9). For elevated diastolic blood pressure (>80 mmHg), the prevalence for young vs. old patients were 28.1 and 28.5%, respectively (P = 0.73). The prevalence of multiple risk factor clustering (BMI 25, cholesterol >4, LDL cholesterol >2 and systolic blood pressure >130) were also similar between young vs. older patients with T2D (Table 2) . 
Discussion
This is the first study to compare CVD risk profiles between young and old patients with T2D in a UK primary care setting, without previous CVD. Our study supports the position of the Joint British Societies (JBS) 2, which suggest that young patients with T2D are a high risk group and that their CVD and metabolic risk profiles were comparable with older patients with type 2 diabetes. Based on this and their potentially higher life-time burden of atherosclerosis, considerations should be made within current guidelines to recognize the increased prevalence of young T2D driven by the rising prevalence of obesity, and public health strategies to prevent CVD in this group of patients. We accept, however, that clinical trial evidence is currently lacking to appropriately guide the development of cardiovascular preventions strategies among young patients with T2D. Furthermore, our study did not adjust for confounding factors such as gender and ethnicity. Nevertheless, extrapolation of current evidence is therefore required to guide clinical management of this challenging group of patients. It is alarming to note the large number of patients with diabetes who are not receiving appropriate cardioprotective drugs. More recently, the benefits of early aggressive management of hyperglycaemia to prevent long-term cardiovascular events through the legacy effects of hyperglycaemia have been clearly demonstrated. 7 To this end, while it is recognized that HbA1c target should be individualized, it is concerning to note that the prevalence of patients with sub-optimal glucose control (HbA1c > 7%) among young patients with T2D is high (57.1%). We have previously shown that among patients attending secondary care diabetes clinic, mean HbA1c was significantly higher in young compared with older patients with T2D 8 . Similarly, previous studies have shown a more adverse lipid profile in young compared with older patients with T2D, 9,10 although these two studies did not adjust for the presence of cardiovascular disease status. Our study which did not include patients with previous cardiovascular events or taking lipid lowering drugs did not support this. Given current guidelines for statin use, 5 it is likely that younger patients with T2D will less likely receive a statin therapy or cardiovascular protective drugs despite displaying a similar lipid profile to older patients with T2D.
The high prevalence of multiple risk factors clustering among young patients with T2D, which is similar to old patients is of important clinical significance. This observation relates to a high prevalence of metabolic syndrome which have been shown to confer up to 5-fold increase in new CVD events among T2D patients without prior history of CVD. 11, 12 Current guideline suggests aggressive cardiovascular risk factor intervention among patients with diabetes with metabolic syndrome 5 . In summary, young patients with T2D presents a growing and a serious problem to clinicians in the UK. Our findings showed similar adverse cardiovascular and metabolic risk profiles between young and older patients with T2D. However, the lack of clinical trial evidence to guide clinical management of this group of patients makes it less likely for patients to receive appropriate cardioprotective drugs. Given their longer disease duration and lifetime risks of atherosclerosis, under-treatment may confer significant burden not only to affected patients, but also to health budgets and the society.
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